Provided by Tiger Trade Technology Pte. Ltd.

CNS Pharmaceuticals, Inc.

5.83
-0.1700-2.83%
Post-market: 5.72-0.1100-1.89%19:30 EDT
Volume:8K
Turnover:48.19K
Market Cap:8.52M
PE:-0.25
High:6.05
Open:5.97
Low:5.83
Close:6.00
52wk High:10.59
52wk Low:1.90
Shares:1.46M
Float Shares:1.35M
Volume Ratio:0.64
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-23.1416
EPS(LYR):-35.7503
ROE:-106.62%
ROA:-58.01%
PB:0.47
PE(LYR):-0.16

Loading ...

Company Profile

Company Name:
CNS Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
8
Office Location:
2100 West Loop South,Suite 900,Houston,Texas,United States
Zip Code:
77027
Fax:
- -
Introduction:
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Directors

Name
Position
Faith L. Charles
Chairman of the Board and Director
Rami Levin
Chief Executive Officer and Director
Amy Mahery
Director
Bettina Cockroft
Director
Jeffry R. Keyes
Director
Michal Fisher
Director

Shareholders

Name
Position
Rami Levin
Chief Executive Officer and Director
Steve O Loughlin
Chief Financial Officer
Eric Faulkner
Chief Technology Officer
Lynne Kelley
Chief Medical Officer